COMMUNIQUÉS West-GlobeNewswire

Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™
29/01/2024
U.S. patent allowance impacts Aging-related Frailty patients receiving vaccines and builds upon a growing patent estate protecting the use of Lomecel-B™ MIAMI, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: [...]
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
29/01/2024
LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to [...]
DLH to Participate in Alliance Global Partners’ Virtual Technology Conference
29/01/2024
ATLANTA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital [...]
Orion publishes Financial Statement Release for 2023 and holds a webcast on 13 February 2024
29/01/2024
ORION CORPORATION PRESS RELEASE 29 January 2024 at 15.00 EET Orion publishes Financial Statement Release for 2023 and holds a webcast on 13 February 2024 Orion will publish Financial Statement Release for 2023 on [...]
Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting
29/01/2024
Oak Ridge, TN, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR) , the global leader in blood volume measurement technology, today announces it will be exhibiting at the Society of Nuclear Medicine and [...]
Corcept Appoints Roberto Vieira as President, Oncology
29/01/2024
MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, [...]
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
29/01/2024
Findings further demonstrate that efzofitimod modulates myeloid cells via the neuropilin-2 (NRP2) receptor to promote a unique anti-inflammatory mechanism. Role of NRP2 in immune system validated by activity of NRP2 [...]
Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program
29/01/2024
Total of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) [...]
Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
29/01/2024
Science 37 stockholders to receive $5.75 per share in cash RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research [...]
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
29/01/2024
MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
29/01/2024
The clinical trial for SCI-210 will be conducted in Israel, after which the company aims to move forward with the commercialization process of SCI-210 first in the Israeli market TEL AVIV, Israel, Jan. 29, 2024 (GLOBE [...]
Leading Veterinary Software Company Instinct Science Acquires VetMedux, Owner of Fast-Growing Clinician's Brief and Plumb’s Veterinary Drugs
29/01/2024
The acquisition brings together the industry’s foremost technology and clinical content expertise to advance the companies’ shared mission to better serve veterinary professionals DOYLESTOWN, Pa. and TULSA, Okla., Jan. [...]
Major shareholder announcement
29/01/2024
Major shareholder announcement January 29, 2024 Company announcement No. 03 On January 29, 2024, following the satisfaction of all conditions precedent, the combination of Novozymes A/S ("Novozymes") and Chr. Hansen [...]
Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya™ as Trade Name for TNX-102 SL for the Management of Fibromyalgia
29/01/2024
Results from two positive Phase 3 studies point to Tonmya’s (TNX-102 SL) potential as a new first-line medicine for chronic use in managing fibromyalgia, a debilitating condition suffered by 6-12 million adults in the U [...]
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
29/01/2024
WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR- [...]
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
29/01/2024
Further expands clinical development of FasTCAR-T GC012F in multiple myeloma amid ongoing U.S. trial evaluating therapy for treatment of relapsed/refractory multiple myeloma SAN DIEGO and SUZHOU, China and SHANGHAI, [...]
ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies
29/01/2024
ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal ® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies Phase 1b open label trial confirms safety and tolerability of 120 mg and 200 mg [...]
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
29/01/2024
The Company now has exclusive rights to a Malaysia, US and China patent SINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based [...]
Oxford Biomedica completes acquisition of ABL Europe
29/01/2024
Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UK [...]

Pages